VIRxSYS Corporation

23 articles about VIRxSYS Corporation

• VIRxSYS Corporation Issued U.S. Patents for its Lentiviral Vector and SMaRT RNA Platforms

  11/15/2011

• VIRxSYS Corporation Issued Third U.S. Patent This Year for its Spliceosome-Mediated RNA Trans-Splicing (SMaRT(TM)) Program; Breakthrough RNA Therapeutic Platform

  9/22/2011

• Functional Cure in Non-Human Primates Achieved With Simian Version of VIRxSYS Corporation' HIV Vaccine VRX1273

  7/18/2011

• Researchers to Present Results From Two VIRxSYS Corporation HIV Studies at the 6th International AIDS Society Meeting

  6/28/2011

• VIRxSYS Corporation Presents New Therapeutic Vaccine Data at HIV DART 2010

  12/9/2010

• VIRxSYS Corporation Demonstrates "Functional Cure" and Survival Benefit for the Simian Model of HIV in Preclinical Vaccine Study

  10/1/2010

• VIRxSYS Corporation Presents Results from Multiple Studies at the 13th ASGCT Annual Meeting

  5/24/2010

• Fight HIV With HIV: 'Safe' Virus Proposed As Vaccine By VIRxSYS Corporation

  2/19/2010

• VIRxSYS Corporation Awarded Maryland Stem Cell Grant

  6/15/2009

• VIRxSYS Corporation Publishes New Study on RNA Therapy

  4/6/2009

• VIRxSYS Corporation to Present at Phacilitate Cell & Gene Therapy Forum

  1/23/2009

• Shuyuan Zhang Joins VIRxSYS Corporation as Senior Director of Production

  8/19/2008

• VIRxSYS Corporation to Host a Web Conference to Announce Clinical Trial Update

  7/22/2008

• VIRxSYS Corporation Takes $8M Of Possible $25M Round

  6/2/2008

• VIRxSYS Corporation Presents New VRX496 Phase II HIV Gene Therapy Trial Data

  5/30/2008

• VIRxSYS Corporation Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia

  3/28/2008

• VIRxSYS Corporation Announces Interim Results from VRX496 Gene Therapy Phase II Trial

  2/7/2008

• VIRxSYS Corporation and Lentigen Corporation Announce Litigation Settlement

  1/15/2008

• VIRxSYS Corporation Announces Acquisition of Intronn

  9/21/2007

• VIRxSYS Corporation Presents Update On HIV Gene Therapy Clinical Trial At ICAAC

  9/18/2007